Clinical Trial Update: A Study to Assess the Safety and Tolerability of BMS-986525 Alone and in Combination With Nivolumab in Participants With Relapsed/Refractory Small Cell Lung Cancer [Phase 1, Phase 2]

View source ↗

Summary

A clinical study to assess the safety and tolerability of BMS-986525 alone and with nivolumab in relapsed/refractory small cell lung cancer, currently recruitin…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Small Cell Lung Cancer

Drugs mentioned

• BMS-986525
• nivolumab (nivolumab)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Relapsed/Refractory Small Cell Lung Cancer | Phase 1, Phase 2 | Status: RECRUITING